Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Amol Dhamane"'
Autor:
Jason G. Andrade, MD, Anshul Shah, BS Pharm, MS, Richard Godin, PhD, Tereza Lanitis, MSc, Thitima Kongnakorn, PhD, Lauren Brown, BSc, Devender Dhanda, PhD, MBA, Amol Dhamane, BPharm, MS, Isabelle Nault, MD
Publikováno v:
Heart Rhythm O2, Vol 4, Iss 2, Pp 103-110 (2023)
Background: Contemporary guidelines recommend opportunistic screening for atrial fibrillation (AF). Objective: The objective of this study was to assess the cost-effectiveness of single time point opportunistic AF screening for patients 65 years and
Externí odkaz:
https://doaj.org/article/13f5ad49a46d48eeb82a03096831da8c
Autor:
Alpesh Amin, Alessandra B Garcia Reeves, Xiaoyan Li, Amol Dhamane, Xuemei Luo, Manuela Di Fusco, Anagha Nadkarni, Keith Friend, Lisa Rosenblatt, Jack Mardekian, Xianying Pan, Huseyin Yuce, Allison Keshishian
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0213614 (2019)
Direct oral anticoagulants (DOACs) are at least as efficacious and safe as warfarin among non-valvular atrial fibrillation (NVAF) patients; limited evidence is available regarding NVAF patients with heart failure (HF). US Medicare enrollees with NVAF
Externí odkaz:
https://doaj.org/article/ab555b9c360b40b4888492a4a3d66bf9
Autor:
Alexander Cohen, Virginia Noxon, Amol Dhamane, Robert Bruette, Shrushti Shah, Dionne M. Hines, Tamuno Alfred, Xuemei Luo
Publikováno v:
Thrombosis Research. 226:117-126
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edb55e812585b8ff85d837b126a9c627
https://doi.org/10.1016/j.thromres.2023.04.009
https://doi.org/10.1016/j.thromres.2023.04.009
Autor:
Gregory Y Lip, Richard Murphy, Farhad Sahiar, Amol Dhamane, Mauricio Ferri, Patrick Hlavacek, Madison Preib, Allison Keshishian, Cristina Russ, Lisa Rosenblatt, Steve Deitelzweig
Publikováno v:
Circulation. 144
Introduction: The CHA 2 DS 2 -VASc score is an established tool to determine the risk of stroke among atrial fibrillation (AF) patients. The goal of this retrospective claims analysis is to evaluate the incidence of stroke/systemic embolism (SE) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2480544ae646dd864976727aa6e8f13e
https://doi.org/10.1161/circ.144.suppl_1.11180
https://doi.org/10.1161/circ.144.suppl_1.11180
Autor:
Alpesh Amin, Allison Keshishian, Oluwaseyi Dina, Amol Dhamane, Anagha Nadkarni, Eric Carda, Cristina Russ, Lisa Rosenblatt, Jack Mardekian, Huseyin Yuce, Christine L. Baker
Publikováno v:
Journal of Thrombosis and Thrombolysis
Atrial fibrillation (AF) prevalence increases with age; > 80% of US adults with AF are aged ≥ 65 years. Compare the risk of stroke/systemic embolism (SE), major bleeding (MB), net clinical outcome (NCO), and major adverse cardiac events (MACE) amon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae9054e982c53a2735f51ffe1cd82bcb
https://doi.org/10.1007/s11239-019-01838-5
https://doi.org/10.1007/s11239-019-01838-5